Filing Details
- Accession Number:
- 0001127602-15-033057
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-12-02 18:20:20
- Reporting Period:
- 2015-12-01
- Filing Date:
- 2015-12-02
- Accepted Time:
- 2015-12-02 18:20:20
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1520262 | Alkermes Plc. | ALKS | Pharmaceutical Preparations (2834) | 981007018 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1487937 | Mark Stejbach | 852 Winter St. Waltham MA 02451 | Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Acquisiton | 2015-12-01 | 18,000 | $17.30 | 37,564 | No | 4 | M | Direct | |
| Ordinary Shares | Disposition | 2015-12-01 | 15,200 | $71.99 | 22,364 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2015-12-01 | 2,300 | $73.09 | 20,064 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2015-12-01 | 500 | $73.58 | 19,564 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Employee Stock Option (Right to Buy) | Disposition | 2015-12-01 | 18,000 | $0.00 | 18,000 | $17.30 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 52,440 | 2013-03-07 | 2022-03-07 | No | 4 | M | Direct |
Footnotes
- This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.39 to $72.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.47 to $73.46. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.48 to $73.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The option becomes exercisable in equal annual installments over a four year period, at the rate of 25% per year commencing on 3/7/13.
Billionaire Hedge Funds
